Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue

Kenneth Nephew, Carol M. Choi, Tara C. Polek, Rosalie McBride, Robert Bigsby, Sohaib A. Khan, Nader Husseinzadeh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective. The objective of this study was to evaluate expression of fos and jun proto-oncogenes in benign human uterine tissue compared with malignant uterine tissue. Methods. Forty-two endometrial tissue specimens were obtained at the time of hysterectomy. Tissue samples from different phases of the menstrual cycle and from postmenopausal patients were stained using immunohistochemical methods to detect Fos and Jun proteins, estrogen and progesterone receptor status, and Ki67 (detects a nuclear antigen associated with proliferating cells). Tissue was examined microscopically for nuclear staining in endometrial epithelium and stroma. The endometrium was based on the patient's last menstrual period, pathologic dating, and proliferative versus nonproliferative status as determined by Ki67. Benign and malignant specimens were subjected to Northern blot analysis to evaluate levels of expression of c-fos, c-jun, and jun-B mRNA. The pattern of c-fos mRNA expression in malignant samples was further evaluated using in situ hybridization. Results. In proliferative, secretory, postmenopausal, and progesterone-influenced, uterine specimens immunohistochemically stained and examined, the endometrial and stromal nuclei stained for both Fos and Jun in varying intensities. However, no pattern was found in the variation of intensity according to the phase of the endometrium. Similarly, in malignant and benign endometrial tissue examined by Northern blot and in situ hybridization analyses, expression of proto-oncogene mRNAs was readily detectable, but no statistical correlation between type of tissue examined, grade of adenocarcinoma, and stage of endometrial cancer was found in this study. Conclusions. In rodent models, control of uterine cell proliferation is related to change in expression of fos and jun protooncogenes. Our results indicate that hormonal control is likely to be different in human endometrium and probably involves genes other than the proto-oncogenes under study. Expression of Fos and Jun do not correlate with endometrial cancer stage and grade. (C) 2000 Academic Press.

Original languageEnglish
Pages (from-to)388-396
Number of pages9
JournalGynecologic Oncology
Volume76
Issue number3
DOIs
StatePublished - Mar 2000

Fingerprint

jun Genes
Endometrium
Proto-Oncogenes
Endometrial Neoplasms
Northern Blotting
Messenger RNA
In Situ Hybridization
Rodent Control
Nuclear Antigens
Progesterone Receptors
Menstrual Cycle
Hysterectomy
Estrogen Receptors
Progesterone
Adenocarcinoma
Epithelium
Cell Proliferation
Staining and Labeling

Keywords

  • Endometrial cancer
  • fos
  • jun
  • Proto-oncogenes
  • Uterus

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue. / Nephew, Kenneth; Choi, Carol M.; Polek, Tara C.; McBride, Rosalie; Bigsby, Robert; Khan, Sohaib A.; Husseinzadeh, Nader.

In: Gynecologic Oncology, Vol. 76, No. 3, 03.2000, p. 388-396.

Research output: Contribution to journalArticle

Nephew, Kenneth ; Choi, Carol M. ; Polek, Tara C. ; McBride, Rosalie ; Bigsby, Robert ; Khan, Sohaib A. ; Husseinzadeh, Nader. / Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue. In: Gynecologic Oncology. 2000 ; Vol. 76, No. 3. pp. 388-396.
@article{22c0d02a21244438a562a794dc369453,
title = "Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue",
abstract = "Objective. The objective of this study was to evaluate expression of fos and jun proto-oncogenes in benign human uterine tissue compared with malignant uterine tissue. Methods. Forty-two endometrial tissue specimens were obtained at the time of hysterectomy. Tissue samples from different phases of the menstrual cycle and from postmenopausal patients were stained using immunohistochemical methods to detect Fos and Jun proteins, estrogen and progesterone receptor status, and Ki67 (detects a nuclear antigen associated with proliferating cells). Tissue was examined microscopically for nuclear staining in endometrial epithelium and stroma. The endometrium was based on the patient's last menstrual period, pathologic dating, and proliferative versus nonproliferative status as determined by Ki67. Benign and malignant specimens were subjected to Northern blot analysis to evaluate levels of expression of c-fos, c-jun, and jun-B mRNA. The pattern of c-fos mRNA expression in malignant samples was further evaluated using in situ hybridization. Results. In proliferative, secretory, postmenopausal, and progesterone-influenced, uterine specimens immunohistochemically stained and examined, the endometrial and stromal nuclei stained for both Fos and Jun in varying intensities. However, no pattern was found in the variation of intensity according to the phase of the endometrium. Similarly, in malignant and benign endometrial tissue examined by Northern blot and in situ hybridization analyses, expression of proto-oncogene mRNAs was readily detectable, but no statistical correlation between type of tissue examined, grade of adenocarcinoma, and stage of endometrial cancer was found in this study. Conclusions. In rodent models, control of uterine cell proliferation is related to change in expression of fos and jun protooncogenes. Our results indicate that hormonal control is likely to be different in human endometrium and probably involves genes other than the proto-oncogenes under study. Expression of Fos and Jun do not correlate with endometrial cancer stage and grade. (C) 2000 Academic Press.",
keywords = "Endometrial cancer, fos, jun, Proto-oncogenes, Uterus",
author = "Kenneth Nephew and Choi, {Carol M.} and Polek, {Tara C.} and Rosalie McBride and Robert Bigsby and Khan, {Sohaib A.} and Nader Husseinzadeh",
year = "2000",
month = "3",
doi = "10.1006/gyno.1999.5696",
language = "English",
volume = "76",
pages = "388--396",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue

AU - Nephew, Kenneth

AU - Choi, Carol M.

AU - Polek, Tara C.

AU - McBride, Rosalie

AU - Bigsby, Robert

AU - Khan, Sohaib A.

AU - Husseinzadeh, Nader

PY - 2000/3

Y1 - 2000/3

N2 - Objective. The objective of this study was to evaluate expression of fos and jun proto-oncogenes in benign human uterine tissue compared with malignant uterine tissue. Methods. Forty-two endometrial tissue specimens were obtained at the time of hysterectomy. Tissue samples from different phases of the menstrual cycle and from postmenopausal patients were stained using immunohistochemical methods to detect Fos and Jun proteins, estrogen and progesterone receptor status, and Ki67 (detects a nuclear antigen associated with proliferating cells). Tissue was examined microscopically for nuclear staining in endometrial epithelium and stroma. The endometrium was based on the patient's last menstrual period, pathologic dating, and proliferative versus nonproliferative status as determined by Ki67. Benign and malignant specimens were subjected to Northern blot analysis to evaluate levels of expression of c-fos, c-jun, and jun-B mRNA. The pattern of c-fos mRNA expression in malignant samples was further evaluated using in situ hybridization. Results. In proliferative, secretory, postmenopausal, and progesterone-influenced, uterine specimens immunohistochemically stained and examined, the endometrial and stromal nuclei stained for both Fos and Jun in varying intensities. However, no pattern was found in the variation of intensity according to the phase of the endometrium. Similarly, in malignant and benign endometrial tissue examined by Northern blot and in situ hybridization analyses, expression of proto-oncogene mRNAs was readily detectable, but no statistical correlation between type of tissue examined, grade of adenocarcinoma, and stage of endometrial cancer was found in this study. Conclusions. In rodent models, control of uterine cell proliferation is related to change in expression of fos and jun protooncogenes. Our results indicate that hormonal control is likely to be different in human endometrium and probably involves genes other than the proto-oncogenes under study. Expression of Fos and Jun do not correlate with endometrial cancer stage and grade. (C) 2000 Academic Press.

AB - Objective. The objective of this study was to evaluate expression of fos and jun proto-oncogenes in benign human uterine tissue compared with malignant uterine tissue. Methods. Forty-two endometrial tissue specimens were obtained at the time of hysterectomy. Tissue samples from different phases of the menstrual cycle and from postmenopausal patients were stained using immunohistochemical methods to detect Fos and Jun proteins, estrogen and progesterone receptor status, and Ki67 (detects a nuclear antigen associated with proliferating cells). Tissue was examined microscopically for nuclear staining in endometrial epithelium and stroma. The endometrium was based on the patient's last menstrual period, pathologic dating, and proliferative versus nonproliferative status as determined by Ki67. Benign and malignant specimens were subjected to Northern blot analysis to evaluate levels of expression of c-fos, c-jun, and jun-B mRNA. The pattern of c-fos mRNA expression in malignant samples was further evaluated using in situ hybridization. Results. In proliferative, secretory, postmenopausal, and progesterone-influenced, uterine specimens immunohistochemically stained and examined, the endometrial and stromal nuclei stained for both Fos and Jun in varying intensities. However, no pattern was found in the variation of intensity according to the phase of the endometrium. Similarly, in malignant and benign endometrial tissue examined by Northern blot and in situ hybridization analyses, expression of proto-oncogene mRNAs was readily detectable, but no statistical correlation between type of tissue examined, grade of adenocarcinoma, and stage of endometrial cancer was found in this study. Conclusions. In rodent models, control of uterine cell proliferation is related to change in expression of fos and jun protooncogenes. Our results indicate that hormonal control is likely to be different in human endometrium and probably involves genes other than the proto-oncogenes under study. Expression of Fos and Jun do not correlate with endometrial cancer stage and grade. (C) 2000 Academic Press.

KW - Endometrial cancer

KW - fos

KW - jun

KW - Proto-oncogenes

KW - Uterus

UR - http://www.scopus.com/inward/record.url?scp=0034015595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034015595&partnerID=8YFLogxK

U2 - 10.1006/gyno.1999.5696

DO - 10.1006/gyno.1999.5696

M3 - Article

C2 - 10684716

AN - SCOPUS:0034015595

VL - 76

SP - 388

EP - 396

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -